Cardinal Health: Why the Bull Case Has a Moderate Score

Cardinal Health stock carries an Alpha Score of 58, labeled Moderate, after a contributor downgraded the shares specifically on the fiscal 2026 earnings view – the Cardinal Health Rating Cut – Contributor Downgrades on 2026E View laid out the case. That assessment contrasts with a bullish Seeking Alpha article that calls the distributor a buy, emphasizing its essential role in pharmaceutical and medical product distribution. The two takes frame a single question: can Cardinal Health sustain its distribution margins while growing its specialty pharmacy business, and is the current price already reflecting those hopes?

The downgrade referenced a view that the $10.80 EPS target for fiscal 2026 looks optimistic given pressure on generic drug margins and potential regulatory changes in pharmacy benefit management. That target, set by management at a recent investor day, underpins much of the bull case. If the company misses that number, traders expect the multiple to compress further.

Specialty pharmacy is Cardinal's main growth engine. The segment includes Navitus, a PBM subsidiary, and a network of specialty pharmacies that handle high-cost drugs for cancer and autoimmune conditions. The Federal Trade Commission's ongoing probe into PBM rebate practices creates uncertainty. Any new rule that limits rebates or forces pass-through to patients could hit revenue for PBMs like Navitus. That risk is not fully captured in the $10.80 projection, according to some analysts.

On the core distribution side, Cardinal's largest customers face their own margin pressures. Walgreens has closed stores and is restructuring. CVS is cutting costs. Hospital systems are consolidating and demanding better pricing. A change in contract terms or volume from any major customer would directly affect Cardinal's top line. The distribution business operates on thin margins, so even a small volume decline hurts earnings.

The next test comes with the fiscal first-quarter earnings report, expected in early November. Cardinal will provide updated guidance for the full year. The contributor downgrade suggests the risk leans toward a downward revision. If management holds the $10.80 target, traders expect the stock to stabilize. A cut would likely push the shares lower, given the moderate Alpha Score already signals caution.

The bullish Seeking Alpha article argues that Cardinal's scale and irreplaceable logistics network make it a safe long-term holding. That may be true over a multiyear horizon. Over the next 12 months, the risk is that earnings miss the high end of expectations and the stock re-rates. The contributor downgrade and the Alpha Score of 58 suggest the market is already pricing in some of that doubt. The question is how much.

The stock trades near 11 times the $10.80 target, a discount to the sector average. That discount exists for a reason. The next earnings report will show whether the pessimism is warranted or the bulls have the better read.